


AMENDMENTS TO THE CLAIMS

1. (Currently amended) A compound of Formula (I)



Formula (I)

wherein:

A represents 4-isopropylphenyl, 4-*tert*.-butylphenyl, ~~4-cyclopropylphenyl,~~ 3-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-bromophenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-(1-hydroxy-1-methyl-ethyl)-phenyl, 3-chloro-4-methylphenyl, 2-methoxy-4-methylphenyl, 3,4-difluorophenyl, 1,2,3,4-tetrahydroisoquinolin-7-yl, 2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl, 2-formyl-1,2,3,4-tetrahydroisoquinolin-7-yl, phenylethenyl, 1-naphthyl, 2-naphthyl, 3-methyl-pyridin-2-yl, 5-methyl-pyridin-2-yl, 5-isopropyl-pyridin-2-yl, or 6-dimethylaminopyridin-3-yl, ~~6-bromo-5-chloro-pyridin-3-yl or 8-quinolinyl;~~

B represents a phenyl, a 6-membered heteroaryl or a nine- or ten-membered bicyclic heteroaryl group, which groups are unsubstituted or independently mono- or di- substituted with cyano, halogen, hydroxy, lower alkyl, hydroxy lower alkyl, amino lower alkyl, aminocarbonyl lower alkyl, sulfonylamino lower alkyl, lower alkenyl, lower alkoxy, trifluoromethyl, trifluoromethoxy, cycloalkyloxy, aryloxy, aralkyloxy, heterocyclyloxy, heterocyclyl lower alkyloxy, amino, aminocarbonyl or sulfonylamino; or a cyclohexyl, 3-piperidinyl or 4-piperidinyl group, which groups are unsubstituted or mono-substituted with hydroxy, lower alkyl, hydroxy lower alkyl, aminocarbonyl lower alkyl, sulfonylamino lower alkyl, amino, aminocarbonyl or sulfonylamino;

with the proviso that in case A represents 2-methylphenyl- or 4-bromophenyl the phenyl ring as represented by B is substituted;

R¹ represents lower alkyl, cycloalkyl, hydroxy lower alkyl or cyano lower alkyl;

R² represents lower alkyl, lower alkenyl, hydroxy lower alkyl, amino lower alkyl, sulfonylamino lower alkyl, cycloalkyl; an unsubstituted or mono- or disubstituted phenyl group substituted independently with cyano, halogen, hydroxy, lower alkyl, lower alkoxy, cycloalkyloxy, amino, amino lower alkyl, aminocarbonyl or sulfonylamino; an unsubstituted or mono- or di-substituted five- or six-membered heteroaryl group substituted independently with cyano, halogen, hydroxy, lower alkyl, lower alkoxy, cycloalkyloxy, amino, amino lower alkyl, aminocarbonyl or sulfonylamino; or an unsubstituted or mono- or di-substituted nine- or ten-membered bicyclic heteroaryl group substituted independently with cyano, halogen, hydroxy, lower alkyl, lower alkoxy, cycloalkyloxy, amino, amino lower alkyl, aminocarbonyl or sulfonylamino;

[[and]] or a pure enantiomers enantiomer, mixtures a mixture of enantiomers, a pure diastereoisomers diastereoisomer, mixtures a mixture of diastereoisomers, a diastereoisomeric racemates racemate, mixtures a mixture of diastereoisomeric racemates, [[and]] or the meso-form, [[and]] or a pharmaceutically acceptable [[salts]] salt, solvent complexes complex, [[and]] or morphological [[forms]] form, thereof.

2. (Cancelled).

3. (Currently amended) The compound of claim 1, wherein[[:]]

A represents a 4-isopropylphenyl group[[:]]

~~and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.~~

4. (Currently amended) The compound of claim 1, wherein[[:]]

A represents a 4-tert.-butylphenyl group[[:]]

~~and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.~~

5-6. (Cancelled).

7. (Currently amended) The compound of claim 1, wherein[[:]]

A represents a 4-(1-hydroxy-1-methyl-ethyl)-phenyl group[[:]]

~~and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.~~

8. (Currently amended) The compound of claim 1, wherein[[:]]

A represents a 3-chloro-4-methylphenyl group[[:]]

~~and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.~~

9. (Currently amended) The compound of claim 1, wherein[[:]]

A represents a 2-formyl-1,2,3,4-tetrahydroisoquinolin-7-y1 group[[:]]

~~and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.~~

10. (Currently amended) The compound of claim 1, wherein[[:]]

A represents a 2-naphthyl group[[:]]

~~and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.~~

11. (Currently amended) The compound of claim 1, wherein[[:]]

A represents a 3-methyl-pyridin-2-yl group[[:]]

~~and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.~~

12. (Currently amended) The compound of claim 1, wherein[[:]]

A represents a 5-isopropyl-pyridin-2-yl group[[:]]

~~and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.~~

13. (Currently amended) The compound of claim 1, wherein[[:]]

A represents a 6-dimethylamino-pyridin-3-yl group[[:]]

~~and pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso form and pharmaceutically acceptable salts, solvent complexes, and morphological forms, thereof.~~

14. (Currently amended) A compound according to claim 1, selected from the group consisting of

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N,N*-diethyl-acetamide;
2-[(4-tert-Butyl-benzenesulfonyl)-(4-methoxy-phenyl)-amino]-*N,N*-diethyl-
acetamide;
2-[(4-tert-Butyl-benzenesulfonyl)-(3-methoxy-phenyl)-amino]-*N,N*-diethyl-
acetamide;
2-[(4-tert-Butyl-benzenesulfonyl)-m-tolyl-amino]-*N,N*-diethyl-acetamide;
2-[(6-Dimethylamino-pyridine-3-sulfonyl)-p-tolyl-amino]-*N*-ethyl-*N*-pyridin-
2-ylmethyl-acetamide;
N-Benzyl-2-[(4-tert-butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-ethyl-
acetamide;
2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-ethyl-*N*-pyridin-4-
ylmethyl-acetamide;
~~*N,N*-Diethyl-2-[(2-methoxy-phenyl)-(toluene-2-sulfonyl)-amino]-acetamide;~~
~~*N*-Benzyl-*N*-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-~~
~~acetamide;~~
~~*N*-Benzyl-*N*-ethyl-2-[(2-methoxy-phenyl)-(toluene-2-sulfonyl)-amino]-~~
~~acetamide;~~
N-Benzyl-2-[(4-tert-butyl-benzenesulfonyl)-(2-methoxy-phenyl)-amino]-*N*-
ethyl-acetamide;
N-Benzyl-*N*-ethyl-2-[(6-methoxy-pyridin-3-yl)-(naphthalene-2-sulfonyl)-
amino]-acetamide;
2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-ethyl-*N*-(2-hydroxy-
ethyl)-acetamide;
2-[(3-Chloro-4-methyl-benzenesulfonyl)-p-tolyl-amino]-*N,N*-diethyl-
acetamide;
N-Benzyl-2-[(4-tert-butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-(2-hydroxy-
ethyl)-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-(2-cyano-ethyl)-*N*-ethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-ethyl-*N*-pyridin-2-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-ethyl-*N*-pyridin-3-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-ethyl-*N*-(6-methylpyridin-2-ylmethyl)-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-ethyl-*N*-thiazol-2-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(3-dimethylamino-phenyl)-amino]-*N,N*-diethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(3-dimethylamino-phenyl)-amino]-*N*-ethyl-*N*-pyridin-2-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(3-dimethylamino-phenyl)-amino]-*N*-ethyl-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-ethyl-*N*-(3-hydroxybenzyl)-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(1H-indazol-6-yl)-amino]-*N*-ethyl-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(1H-indazol-6-yl)-amino]-*N*-ethyl-*N*-pyridin-2-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-(2-hydroxy-ethyl)-*N*-pyridin-2-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(3-dimethylamino-phenyl)-amino]-*N*-(2-hydroxy-ethyl)-*N*-pyridin-2-ylmethyl-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-p-tolyl-amino]-*N*-cyclopropyl-*N*-(3-methoxy-benzyl)-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(3-dimethylamino-phenyl)-amino]-*N*-cyclopropyl-*N*-(3-methoxy-benzyl)-acetamide;

~~*N*-Ethyl-2-[(2-methoxy-phenyl)-(toluene-2-sulfonyl)-amino]-*N*-thiazol-2-ylmethyl-acetamide;~~

~~*N*-Benzyl-*N*-(2-hydroxy-ethyl)-2-[(2-methoxy-phenyl)-(toluene-2-sulfonyl)-amino]-acetamide;~~

~~*N*-Ethyl-2-[(2-methoxy-phenyl)-(toluene-2-sulfonyl)-amino]-*N*-pyridin-2-ylmethyl-acetamide;~~

~~*N*-Ethyl-*N*-(3-hydroxy-benzyl)-2-[(2-methoxy-phenyl)-(toluene-2-sulfonyl)-amino]-acetamide;~~

~~*N*-Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide;~~

~~*N*-Benzyl-*N*-(2-hydroxy-ethyl)-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-acetamide;~~

~~*N*-Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-*N*-pyridin-3-ylmethyl-acetamide;~~

~~*N*-Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-*N*-pyridin-2-ylmethyl-acetamide;~~

~~*N*-Ethyl-2-[(2-methoxy-phenyl)-(3-methyl-pyridine-2-sulfonyl)-amino]-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide;~~

N-Ethyl-2-[(2-methoxy-phenyl)-(3-methyl-pyridine-2-sulfonyl)-amino]-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide;

~~*N*-Benzyl-*N*-ethyl-2-[(2-methoxy-phenyl)-(3-methyl-pyridine-2-sulfonyl)-amino]-acetamide;~~

N-Benzyl-*N*-ethyl-2-[(2-methoxy-phenyl)-(3-methyl-pyridine-2-sulfonyl)-amino]-acetamide;

2-[(4-tert-Butyl-benzenesulfonyl)-(6-methyl-pyridin-3-yl)-amino]-*N*-ethyl-*N*-pyridin-2-ylmethyl-acetamide;

N-Benzyl-2-[(4-tert-butyl-benzenesulfonyl)-(6-methyl-pyridin-3-yl)-amino]-*N*-ethyl-acetamide;

~~*N*-Ethyl-2-[(6-methoxy-pyridin-3-yl)-(3-methyl-pyridine-2-sulfonyl)-amino]-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide~~

N-Ethyl-2-[(6-methoxy-pyridin-3-yl)-(3-methyl-pyridine-2-sulfonyl)-amino]-*N*-(6-methyl-pyridin-2-ylmethyl)-acetamide; and

~~*N*-Benzyl-*N*-ethyl-2-[(6-methoxy-pyridin-3-yl)-(3-methyl-pyridine-2-sulfonyl)-amino]-acetamide~~;

N-Benzyl-*N*-ethyl-2-[(6-methoxy-pyridin-3-yl)-(3-methyl-pyridine-2-sulfonyl)-amino]-acetamide.

15. (Previously presented) A pharmaceutical composition, comprising one or more compounds of claim 1, or a pharmaceutically acceptable salt thereof, as active ingredients, and a pharmaceutically acceptable carrier or adjuvant, or both.

16-19. (Cancelled).

20. (Currently amended) A process for the manufacture of the pharmaceutical composition of claim 15, comprising mixing one or more active ingredient or ingredients with ~~[[a]] the pharmaceutically acceptable excipient~~ carrier or adjuvant, or both.

21-22. (Cancelled).

23. (Previously presented) The pharmaceutical composition of claim 15 further comprising an additional pharmacologically active compound.

24. (Previously presented) The pharmaceutical composition of claim 23, wherein the additional pharmacologically active compound is selected from the group consisting of other orexin receptor antagonists, lipid lowering agents, anorectic agents, sleep inducing agents, antidepressants, other drugs beneficial for the prevention or treatment of diseases or disorders where an antagonist of human orexin receptors is required,

eating disorders, sleep disorders, cardiovascular disorders, cancer, pain, depression, anxiety, schizophrenia, neurodegenerative disorders and hyperthermia syndromes.

25-26. (Cancelled).